#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

IFM Therapeutics appoints Michael Cooke as chief scientific officer

Share on Twitter Share on LinkedIn
Christian Fernsby | Boston, Mass., USA | January 7, 2020
IFM TherapeuticsIFM Therapeutics, a biopharmaceutical company, announced the appointment of Michael Cooke as chief scientific officer.
Dr. Cooke joins IFM from Magenta Therapeutics where he most recently served as Chief Scientific Officer.

Prior to Magenta, Dr. Cooke was a founding scientist at the Genomics Institute of the Novartis Research Foundation, where he held several positions including Executive Director of Immunology.

Dr. Cooke previously served as Director of Functional Genomics at SyStemix in the area of hematopoietic stem cell biology.

Dr. Cooke earned a B.A. in Biochemistry from the University of California, Santa Barbara and a Ph.D. in Biochemistry from the University of Washington.

He completed postdoctoral research on the molecular basis of B cell tolerance with Dr. Christopher Goodnow at Stanford University.


 LATEST MOVES FROM Massachusetts 


MORE INSIDE POST